The consideration of CYP2C19 genotyping before VCZ treatment may be helpful in the management of high-risk populations, such as patients with hepatic insufficiency or those receiving medications that may increase the risk of VCZ toxicity by drug-drug interactions (e.g., proton- pump inhibitors) [ 30]. Here, CYP2C19 is linked to Hepatic failure.